Because macular telangiectasia is considered a fairly rare condition, there is still much we don’t fully understand. We do know that some patients may only need careful monitoring and may not need ...

Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long alternative to intravitreal injections.